医学
硼替佐米
内科学
入射(几何)
多发性骨髓瘤
蛋白酶体抑制剂
肺
外科
肿瘤科
光学
物理
作者
Harumi Y. Mukai,Kazuma Ohyashiki,Takao Katoh,Masahiko Kusumoto,Akihiko Gemma,Humikazu Sakai,Yukihiko Sugiyama,Kiyohiko Hatake,Yuh Fukuda,Shoji Kudoh
出处
期刊:PubMed
日期:2011-12-01
卷期号:52 (12): 1859-69
被引量:2
摘要
Bortezomib (Velcade(®)), a proteasome inhibitor, was launched for the treatment of relapsed or refractory multiple myeloma in Japan in December 2006. Prior to approval in Japan, high incidence (15.2%) and mortality (6.5%) of bortezomib therapy-related lung disorders were reported with private import treatment. Therefore the Velcade Lung Disorder Panel (the Panel) was established and the cases have been reviewed. A total of 3,556 patients, including 823 post-marketing surveillance (PMS) patients, have received bortezomib since April 25, 2009. The incidence of lung disorders associated with bortezomib therapy was 2.33% (3.77% in case of PMS). The panel reviewed the detailed information of 70 cases and classified the CT and X-ray images as follows: (1)Interstitial pneumonia; diffuse alveolar damage pattern, hypersensitivity pneumonia pattern and others (2)Vascular hyperpermiability; (non-cardiogenic) pulmonary edema pattern and capillary leak syndrome-like pattern (3)Hypoxia. These post-marketing data showed that the incidence of lung disorders in Japan was lower than expected based on private import data.
科研通智能强力驱动
Strongly Powered by AbleSci AI